Theriva Biologics Inc(TOVX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 7:23 PM ET (Korea 11/7 09:23)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.67 | Insider Own | 1.63% | Shs Outstand | 45.9M | Perf Week | -2.35% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 20% | Insider Trans | - | Shs Float | 45.1M | Perf Month | -26.68% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.06 | Inst Own | 4.39% | Short Float | 4.09% | Perf Quarter | -27.92% |
| Income | -0.01B | P/S | 25.48 | EPS this Y | 87.98% | Inst Trans | 0.05% | Short Ratio | 0.93 | Perf Half Y | -52.97% |
| Sales | 0.00B | P/B | 0.63 | EPS next 5Y | - | ROA | -32.87% | Short Interest | 1.85M | Perf YTD | -20.87% |
| Book/sh | 0.27 | P/C | 0.67 | EPS past 3/5Y | 60.07% 58.31% | ROE | -101.87% | 52W High | -66.16% ($0.49) | Perf Year | -39.08% |
| Cash/sh | 0.25 | P/FCF | - | Sales past 3/5Y | - | ROIC | -76.53% | 52W Low | 22.43% ($0.14) | Perf 3Y | -98.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.38% | Gross Margin | 65.67% | Volatility(W/M) | 22.63% 10.22% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | -0.49 | Sales Y/Y TTM | - | Oper. Margin | -4224.33% | ATR (14) | 0.02 | Perf 10Y | -100% |
| Dividend Ex-Date | 2007/12/27 | Quick Ratio | 1.13 | EPS Q/Q | 96.37% | Profit Margin | -4376% | RSI (14) | 32.58 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.13 | Sales Q/Q | - | SMA20 | -14.17% ($0.2) | Beta | 1.23 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.29 | Earnings | 2026/8/11 | SMA50 | -23.63% ($0.22) | Rel Volume | 0.21 | Prev Close | $0.17 |
| Employees | 16 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | -27.27% - | SMA200 | -30.3% ($0.24) | Avg Volume(3M) | 1.98M | Price | $0.17 |
| IPO | 1993/4/5 | Option/Short | No/Yes | Trades | 527 | Volume | 407,551 | Change | -1.13% |
🧬 Theriva Biologics () is a clinical-stage biotech developing treatments for refractory cancers using an oncolytic adenovirus that selectively replicates in tumor cells. Its lead candidate, VCN-01, met the primary endpoints of overall survival and safety in a Phase 2b trial for metastatic pancreatic cancer, and a Phase 3 design consultation with the FDA is scheduled for the first half of 2026—positioning it as a small-cap cancer therapeutics stock with key clinical catalysts ahead.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded less than usual. That is 21% of its average volume.
TOVX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +88.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,548. Peers typically go for $917.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #516 of 597 in the industry
Based on market cap of $8M.
TOVX#516 Theriva Biologics Inc $8M PER - 
TPST#517 Tempest Therapeutics Inc $8M PER - 
CLGN#518 CollPlant Biotechnologies Ltd $8M PER - 
APRE#519 Aprea Therapeutics Inc $7M PER - 
SNGX#520 Soligenix Inc $7M PER - 
FAQ
What kind of company is TOVX?
TOVX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TOVX?
The market cap of TOVX is approximately $8M, ranking 5,488 within its sector.
What is the 52-week high and low for TOVX?
TOVX has recorded a 52-week high of $0.49 and a low of $0.14.
